TARIBAVIRIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C8H13N5O4
Molecular Weight	243.2199
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC(=N)C1=NN(C=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O

InChI

InChIKey=NHKZSTHOYNWEEZ-AFCXAGJDSA-N

InChI=1S/C8H13N5O4/c9-6(10)7-11-2-13(12-7)8-5(16)4(15)3(1-14)17-8/h2-5,8,14-16H,1H2,(H3,9,10)/t3-,4-,5-,8-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C8H13N5O4
Molecular Weight	243.2199
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://clinicaltrials.gov/ct2/show/NCT00230958 | https://www.ncbi.nlm.nih.gov/pubmed/19040344 | https://ir.bauschhealth.com/news-releases/2010/01-11-2010

Taribavirin, an oral prodrug of ribavirin that was developed as nucleoside antimetabolite, which interferes with duplication of viral genetic material. Taribavirin was studied in phase III clinical trial for the treatment of chronic hepatitis C patients. However, this drug not yet approved for pharmaceutical use.

Originator

Approval Year

PubMed

Title	Date	PubMed
Synthesis and antiviral activity of 1,2,4-triazole-3-thiocarboxamide and 1,2,4-triazole-3-carboxamidine ribonucleosides.	1973 Aug	4355593
Effects of ribamidine, a 3-carboxamidine derivative of ribavirin, on experimentally induced Phlebovirus infections.	1988 Dec 1	2976263
Treatment of lethal Pichinde virus infections in weanling LVG/Lak hamsters with ribavirin, ribamidine, selenazofurin, and ampligen.	1993 Jan	8384433
Antiviral and immunomodulating inhibitors of experimentally-induced Punta Toro virus infections.	1994 Oct	7847873
Identification of active antiviral compounds against a New York isolate of West Nile virus.	2002 Jul	12076755
Viramidine (Ribapharm).	2002 Nov	12476957
A simple assay for determining antiviral activity against Crimean-Congo hemorrhagic fever virus.	2004 Apr	15026198
Dual-action mechanism of viramidine functioning as a prodrug and as a catabolic inhibitor for ribavirin.	2004 Oct	15388466
In vitro and in vivo influenza virus-inhibitory effects of viramidine.	2005 Oct	16087250
Virological response and safety outcomes in therapy-nai ve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study.	2007 Jul	17470380
Therapeutic issues in HIV/HCV-coinfected patients.	2007 Jun	17501757
Taribavirin for the treatment of chronic hepatitis C.	2008 Dec	19040344
Ribavirin analogs.	2009 Aug	19628158
A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naïve patients with chronic hepatitis C: ViSER1 results.	2009 Sep	19585653
New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents.	2010	21694902
Hepatitis C and kidney disease.	2010	21188196
Antiviral therapy for hepatitis C virus: beyond the standard of care.	2010 Apr	21994657
Hepatitis C treatment: current and future perspectives.	2010 Nov 1	21040548
The next step for taribavirin.	2010 Oct	20879028
Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C.	2010 Oct	20721883

Sample Use Guides

In Vivo Use Guide

viramidine (TARIBAVIRIN) 600 mg BID

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:04:23 GMT 2023` Edited by `admin` on `Fri Dec 15 16:04:23 GMT 2023`
Record UNII	R3B1994K2E
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TARIBAVIRIN

Official Name

English

TARIBAVIRIN [MI]

Common Name

English

Taribavirin [WHO-DD]

Common Name

English

taribavirin [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C281